IRLAB proposes eliminating about 10 jobs, equal to 30% of its workforce, to prioritize partnerships
Key Facts
IRLAB Therapeutics announced on November 12, 2026, a proposal to eliminate about 10 jobs, mostly in early research and development activities, as part of a shift focused on generating revenue from its existing portfolio through partnerships. The company said the proposed job cuts represent about 30% of its total workforce and remain subject to consultations with employee representatives. A final decision will be made only after those consultations conclude, according to the company’s statement. IRLAB aims to reduce its annual cost base by about 8 million Swedish kronor. It said the significant impact of the cuts is expected from the third quarter of 2027, meaning the full savings will not be immediate.
The job cuts are linked to a change in resource allocation. The company said continued investment in creating new development projects is not currently expected to generate sufficient value for shareholders. Instead of expanding efforts to discover new drug candidates, it intends to devote more resources to commercially exploiting its existing portfolio. The options it identified include forming partnerships, signing licensing agreements or divesting assets. In this context, the company plans to recruit an executive with business development experience for a newly created position of chief business development officer. The position is intended to strengthen efforts to generate revenue from products and programs already in the portfolio, according to the statement.
Regarding new agreements, IRLAB said some potential partners had chosen to halt discussions in recent months. It added that other commercial dialogues remain ongoing and that several new parties have expressed interest. The chairman said the discussions confirm continued interest in the portfolio, but noted that reaching agreements is taking longer than previously expected. The company said the likelihood of signing new partnership agreements during the remainder of 2026 had declined, indicating that existing interest has not yet translated into agreements as quickly as it had hoped. This puts the focus of the shift on exploiting existing assets while adjusting expectations for the timing of new partnerships.
The portfolio includes Parkinson’s disease treatment programs at different stages of development. Mesdopetam has completed Phase IIb, and the company is preparing for Phase III, while pirepemat is in Phase IIb. Linepamat is in Phase Ib, alongside two preclinical programs. The reduction in resources allocated to discovering new candidates comes as the company seeks to generate commercial value from these existing programs through partnerships, licensing or divestment. The differing development stages provide context for the company’s commercial options, which span both advanced programs and others still at an early stage.
Company data for January to September 2026 show that cash and cash equivalents stood at 90.6 million Swedish kronor at the end of the period, compared with 110.1 million kronor in the same period of 2025. In the third quarter of 2026, the company recorded net sales of 6.9 million kronor, versus 18.8 million kronor in the third quarter of 2025. Operating loss narrowed to 12.9 million kronor from a loss of 17.2 million kronor in the comparison period. The share price was 1.83 Swedish kronor at the end of the third quarter of 2026, compared with 2.92 kronor a year earlier. These figures provide financial context for the shift, while the company has set its target annual savings at about 8 million kronor, with a significant impact expected to begin in the third quarter of 2027.
Among upcoming portfolio milestones are results from the Phase Ib LIFT-PD study of linepamat, which the company expects in mid-2027. The drug is being developed in collaboration with Otsuka, which is funding the ongoing clinical study. The company also said its chief executive plans to leave the position during the first quarter of 2027. The management transition coincides with the creation of the chief business development officer role and the redirection of resources toward partnerships and revenue generation. The study results and consultations on the proposed job cuts remain among the upcoming milestones identified in the company’s statement.